A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
Clinical trial NCT03067285 · COMPLETED
Trial details
- NCT number
- NCT03067285
- Sponsor
- Fundacion SEIMC-GESIDA
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2017-09-08
- Primary completion
- 2019-04-23
- Enrollment
- 39
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.